O	0	5	Serum
O	6	17	antioxidant
O	18	26	capacity
O	26	27	,
O	28	39	biochemical
O	40	47	profile
O	48	51	and
O	52	56	body
O	57	68	composition
O	69	71	of
O	72	78	breast
O	79	85	cancer
O	86	95	survivors
O	96	98	in
O	99	100	a
O	101	111	randomized
B-intervention	112	125	Mediterranean
I-intervention	126	133	dietary
O	134	146	intervention
O	147	152	study
O	152	153	.

O	154	164	Increasing
O	165	173	evidence
O	174	182	suggests
O	183	187	that
O	188	201	Mediterranean
O	202	206	Diet
O	207	208	(
O	208	210	MD
O	210	211	)
O	212	214	is
O	215	225	correlated
O	226	230	with
O	231	238	reduced
O	239	243	risk
O	244	246	of
O	247	253	breast
O	254	260	cancer
O	261	262	(
O	262	264	BC
O	264	265	)
O	266	269	and
O	270	276	cancer
O	277	286	mortality
O	286	287	,
O	288	293	since
O	294	296	it
O	297	305	modifies
O	306	314	patients
O	314	315	'
O	316	321	serum
O	322	333	antioxidant
O	334	342	capacity
O	342	343	,
O	344	348	body
O	349	360	composition
O	361	364	and
O	365	376	biochemical
O	377	387	parameters
O	387	388	.

O	389	392	The
O	393	396	aim
O	397	399	of
O	400	403	the
O	404	409	study
O	410	413	was
O	414	416	to
O	417	428	investigate
O	429	436	whether
O	437	438	a
O	439	446	dietary
O	447	459	intervention
O	460	465	based
O	466	468	on
O	469	471	MD
O	472	475	has
O	476	477	a
O	478	488	beneficial
O	489	495	effect
O	496	498	on
O	499	504	these
O	505	512	factors
O	512	513	.

O	514	516	In
O	517	521	this
O	522	534	intervention
O	535	540	study
O	540	541	,
B-total-participants	542	549	seventy
B-eligibility	550	556	female
I-eligibility	557	559	BC
I-eligibility	560	569	survivors
O	570	574	were
O	575	583	randomly
O	584	592	assigned
O	593	595	to
O	596	597	(
O	597	598	1
O	598	599	)
O	600	603	the
O	604	616	intervention
O	617	622	group
O	623	624	(
O	624	636	personalized
O	637	644	dietary
O	645	657	intervention
O	658	663	based
O	664	666	on
O	667	669	MD
O	669	670	)
O	671	674	and
O	675	676	(
O	676	677	2
O	677	678	)
O	679	682	the
B-control	683	690	control
I-control	691	696	group
O	697	698	(
O	698	706	received
O	707	710	the
O	711	718	updated
O	719	727	American
O	728	734	Cancer
O	735	742	Society
O	743	753	Guidelines
O	754	756	on
O	757	766	Nutrition
O	767	770	and
O	771	779	Physical
O	780	788	Activity
O	789	792	for
O	793	799	Cancer
O	800	810	Prevention
O	811	814	and
O	815	817	ad
O	818	825	libitum
O	826	830	diet
O	830	831	)
O	831	832	.

O	833	837	Both
O	838	844	groups
O	845	849	were
O	850	858	assessed
O	859	864	twice
O	865	866	[
O	866	875	beginning
O	875	876	,
O	877	880	end
O	881	883	of
O	884	889	study
O	890	891	(
O	891	896	after
O	897	898	6
O	899	905	months
O	905	906	)
O	906	907	]
O	908	917	regarding
O	918	923	their
O	924	938	anthropometric
O	939	942	and
O	943	954	biochemical
O	955	965	parameters
O	965	966	,
O	967	972	serum
O	973	980	vitamin
O	981	982	C
O	982	983	,
O	984	991	vitamin
O	992	993	A
O	993	994	,
O	995	996	a
O	996	997	-
O	997	1007	tocopherol
O	1008	1011	and
O	1012	1017	CoQ10
O	1018	1024	levels
O	1024	1025	,
O	1026	1033	dietary
O	1034	1040	intake
O	1041	1044	and
O	1045	1054	adherence
O	1055	1057	to
O	1058	1060	MD
O	1060	1061	.

O	1062	1064	An
O	1065	1075	additional
O	1076	1088	intermediate
O	1089	1097	analysis
O	1098	1101	was
O	1102	1111	conducted
O	1112	1114	on
O	1115	1127	participants
O	1127	1128	'
O	1129	1133	body
O	1134	1145	composition
O	1146	1149	and
O	1150	1161	biochemical
O	1162	1169	profile
O	1169	1170	.

O	1171	1181	Concerning
O	1182	1185	the
O	1186	1198	intervention
O	1199	1204	group
O	1204	1205	,
B-outcome	1206	1210	body
I-outcome	1211	1217	weight
O	1217	1218	,
B-outcome	1219	1223	body
I-outcome	1224	1227	fat
I-outcome	1228	1232	mass
O	1232	1233	,
B-outcome	1234	1239	waist
I-outcome	1240	1253	circumference
O	1253	1254	,
B-outcome	1255	1259	body
I-outcome	1260	1264	mass
I-outcome	1265	1270	index
O	1271	1273	as
O	1274	1278	well
O	1279	1281	as
B-outcome	1282	1285	HDL
I-outcome	1285	1286	-
I-outcome	1286	1297	cholesterol
O	1298	1302	were
O	1303	1316	significantly
O	1317	1326	decreased
O	1327	1328	(
O	1328	1329	P
O	1330	1331	<
O	1332	1333	0
O	1333	1334	.
O	1334	1335	2
O	1335	1336	%
O	1336	1337	)
O	1337	1338	.

O	1339	1341	An
O	1342	1350	increase
O	1351	1354	was
O	1355	1363	observed
O	1364	1366	in
O	1367	1370	the
B-outcome	1371	1378	vitamin
I-outcome	1379	1380	C
I-outcome	1381	1387	levels
O	1388	1390	in
O	1391	1396	blood
O	1397	1398	(
O	1398	1399	P
O	1400	1401	<
O	1402	1403	0
O	1403	1404	.
O	1404	1405	2
O	1405	1406	%
O	1406	1407	)
O	1407	1408	.

O	1409	1411	In
O	1412	1415	the
O	1416	1423	control
O	1424	1429	group
O	1429	1430	,
B-outcome	1431	1435	body
I-outcome	1436	1442	weight
O	1442	1443	,
B-outcome	1444	1448	body
I-outcome	1449	1452	fat
I-outcome	1453	1457	mass
O	1458	1461	and
B-outcome	1462	1467	serum
I-outcome	1468	1473	total
I-outcome	1474	1485	cholesterol
I-outcome	1486	1490	rose
O	1491	1492	(
O	1492	1493	P
O	1494	1495	<
O	1496	1497	0
O	1497	1498	.
O	1498	1499	2
O	1499	1500	%
O	1500	1501	)
O	1501	1502	.

O	1503	1505	At
O	1506	1509	the
O	1510	1513	end
O	1514	1516	of
O	1517	1520	the
O	1521	1526	study
O	1527	1530	the
O	1531	1534	two
O	1535	1541	groups
O	1542	1546	were
O	1547	1560	significantly
O	1561	1570	different
O	1571	1582	considering
B-outcome	1583	1588	blood
I-outcome	1589	1596	glucose
O	1596	1597	,
B-outcome	1598	1605	vitamin
I-outcome	1606	1607	C
O	1607	1608	,
B-outcome	1609	1624	polyunsaturated
I-outcome	1625	1630	fatty
I-outcome	1631	1636	acids
O	1636	1637	,
B-outcome	1638	1645	vitamin
I-outcome	1646	1647	A
O	1648	1651	and
B-outcome	1652	1653	a
I-outcome	1653	1654	-
I-outcome	1654	1664	tocopherol
I-outcome	1665	1671	levels
O	1671	1672	.

O	1673	1677	This
O	1678	1688	randomized
O	1689	1696	dietary
O	1697	1709	intervention
O	1710	1715	based
O	1716	1718	on
O	1719	1721	MD
O	1722	1729	managed
O	1730	1732	to
O	1733	1743	ameliorate
O	1744	1749	serum
O	1750	1761	antioxidant
O	1762	1770	capacity
O	1770	1771	,
O	1772	1776	body
O	1777	1788	composition
O	1788	1789	,
O	1790	1799	adherence
O	1800	1802	to
O	1803	1805	MD
O	1806	1809	and
O	1810	1818	glycemic
O	1819	1826	profile
O	1827	1829	of
O	1830	1844	postmenopausal
O	1845	1847	BC
O	1848	1857	survivors
O	1857	1858	.
